National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
NCT Number: NCT02169310
Background:
People with a traumatic brain injury (TBI) can have trouble making the best possible decisions. Researchers want to learn more about the parts of the brain that control decision making. They also want to know how these are different between people. This may help predict how people make decisions after TBI.
Objective:
To learn more about which parts of the brain are involved in making decisions and how decisions may be hurt after TBI.
Eligibility:
Adults age 18 to 60.
Design:
Participants will be screened with medical history and physical exam. They will also take memory, attention, concentration, and thinking tests.
Participants will do up to 2 experiments.
For Experiment 1, participants may have 3 scans:
PET: a chemical is injected through a thin tube into an arm vein. Participants lie on a bed that slides in and out of the scanner.
MRI: a strong magnetic field and radio waves take pictures of the brain. Participants lie on a table that slides in and out of a metal cylinder. It makes loud knocking noises. Participants will get earplugs. They might be asked to do a task. A coil will be placed over the head.
MEG: a cone with magnetic field detectors is lowered onto participants head.
After the scans, participants will perform a decision-making task.
For Experiment 2, participants will perform a decision-making task before and after receiving transcranial direct current stimulation (tDCS).
tDCS: wet electrode sponges are placed over participants' scalp and forehead. A current passes between the electrodes. It stimulating the brain.
Participants will return 24-48 hours later to repeat the decision-making task.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Bethesda, Maryland, 20892, United States
Study Description:
Deficits in decision-making are commonly found in individuals after traumatic brain injury (TBI) and can have a severe negative impact on quality of life. Converging evidence from both animal model and human studies suggest that decision-making deficits are linked with abnormal mesocorticolimbic network structure and function, and could potentially be mitigated through interventions that improve function within these neuronal circuits.
Objectives:
Endpoints:
Primary Endpoint: The primary outcome measure for both Experiment 1 and 2 is performance in a computerized decision-making task.
Secondary Endpoints: Secondary outcome measures will include quantitative estimates of structural and functional mesocorticolimbic network features, including MRI-based structural and functional connectivity, MEG-based functional connectivity, baseline dlPFC GABA concentration measured with magnetic resonance spectroscopy (MRS) imaging, dopamine D2 receptor binding potential within mesocorticolimbic subcortical nuclei measured with [11C]raclopride PET (Experiment 1). Multimodal data fusion modeling will be used to explore the predictive relationship between baseline mesocorticolimbic network features and decision-making task performance within a unified state-space framework (Experiment 1), as well as the ability of these network features to predict inter-individual differences in the effects of tDCS on decision-making task performance (Experiment 2).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Healthy Volunteers:
Inclusion criteria
for TBI:
external trauma to the head) physiological disruption of brain function, as manifested by at least one of the following (based on the American Congress of Rehabilitation Medicine Criteria):
Exclusion criteria
There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
[11C] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and [11C] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: [11C] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
Time frame: Participation may be completed over the course of a week, or longer depending on participant s schedule and testing availability. Typically, individuals complete the full study with 4-7 days.
The primary outcome measure for both Experiment 1 and 2 is performance in a computerized decision-making task.
Time frame: Participation may be completed over the course of a week, or longer depending on participant s schedule and testing availability. Typically, individuals complete the full study with 4-7 days.
Secondary outcome measures will include quantitative estimates of structural and functional mesocorticolimbic network features, including MRI-based structural and functional connectivity, MEG-based functional dynamics, baseline dlPFC GABA concentration measured with magnetic resonance spectroscopy (MRS) imaging, dopamine D2 receptor binding potential within mesocorticolimbic subcortical nuclei measured with [11C]raclopride PET (Experiment 1). Multimodal data fusion modeling will be used to explore the predictive relationship between baseline mesocorticolimbic network states and decision-making performance within a unified state-space framework (Experiment 1), as well as the ability of these network states to predict inter-individual differences in the effects of tDCS on decision-making performance (Experiment 2).
National Institute of Neurological Disorders and Stroke (NINDS)
Nih
Neural Basis of Decision Making Deficits in Traumatic Brain Injury
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01287156
Brain Diseases, Brain Injuries
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05714150
Brain Diseases, Brain Injuries
Gainesville, Florida, United States
View Trial DetailsNCT04056312
Brain Diseases, Brain Injuries
West Orange, New Jersey, United States
View Trial DetailsNCT01132937
Brain Diseases, Brain Injuries
Bethesda, Maryland, United States
View Trial Details